BioCurex Presents RECAF Results At International Cancer Congress

Main Category: Cancer / Oncology
Article Date: 15 Aug 2008 - 8:00 PDT

email to a friend   printer friendly   opinions  

BioCurex Inc. (OTCBB:BOCX) announced that the Congress Scientific Committee has accepted its presentation to the ISOBM annual meeting. BioCurex will present results obtained with its ELISA RECAF blood test for cancer at the 2008 assembly of the International Society of Oncology and Bio-Markers (ISOBM).

The conference will be held from October 5th to October 9th, in Tokyo, Japan and will bring together scientists, clinicians and companies involved in the field of cancer markers.

Dr. Moro stated: "This year's conference is entitled, 'Development of new molecular tumor markers for diagnosis and therapy'. The subject is well chosen and critical for good reason: it reflects the acute need, among the scientific community as well as clinicians, for new cancer markers to be used in cancer diagnosis and therapy. This need arises from the fact that there are presently very few markers, their overall performance is not very good and they are limited to a few types of cancer. It also reflects on the fact that since AFP and CEA were first described as cancer markers in the early 60's, not many markers have been discovered. BioCurex has a unique cancer marker in the sense that it combines excellent performance in discriminating patients with cancer from those who do not have cancer, along with the ability to detect very early stages of two of the most common cancers - breast and prostate. RECAF, our marker, also has the potential to be used on a broad spectrum of cancers, which is a tremendous advantage.

At ISOBM 2008 we'll be showing results related to the ELISA format - a type of test that can be carried out in most research and clinical labs. We expect to elicit significant interest among scientists to carry out collaborations that will continue to validate, independently and through numerous publications, the very good performance of the RECAF tests."

To find more about the 2008 ISOBM meeting, go to http://isobm08.umin.jp/index.html

About BioCurex

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAFTM, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.

BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories and with Inverness Medical Innovations (for further information on these agreements see here.)

The cancer marker RECAFTM has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.

To read more about BioCurex, please visit the News section in our web site http://www.biocurex.com.

Note

The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.

BioCurex

• Additional
• References
• Citations